| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 17 | 52.0x | 17.3x | Bottom tier | |
Growth | 59 | 14.6% | 7.1% | Around median | |
Quality | 81 | 8.9% | 4.5% | Top tier | |
Safety | 92 | — | 2.6x | Top tier | |
Capital Return | 48 | 0.00% | 0.06% | Around median | |
Momentum | 77 | 11.6% | -1.6% | Top tier | |
Sentiment | 68 | 16 | 3 | Top tier |
The floor: what the company is worth if growth stopped today
71% of today's price is what a buyer pays for growth that has not happened yet.
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Edwards Lifesciences focuses on treating structural heart disease and generates revenue from valve platforms and related therapies. Its portfolio includes TAVR led by SAPIEN, transcatheter mitral and tricuspid therapies TMTT through PASCAL, EVOQUE, and SAPIEN M3, and surgical solutions such as INSPIRIS, MITRIS, and KONECT based on RESILIA tissue. The growth strategy relies on expanding indications, increasing the number of centers offering therapies, deepening utilization within existing centers, and supporting adoption with long-term clinical evidence.
In Q2 fiscal year 2026, reported revenue reached $1.74 billion, with underlying year-over-year growth of 12.5%, while adjusted earnings per share were $0.78 and generally accepted accounting principles earnings per share were $0.42. EDGAR data show gross profit of approximately $1.3 billion and net income of $241.9 million, equivalent to an approximate net margin of 13.9% based on revenue of $1.74 billion. The adjusted gross profit margin was 77.6%, unchanged year over year, while the adjusted operating profit margin was 30%.
TAVR remained the largest driver, with global revenue of $1.3 billion and growth of 10.5%, representing approximately three-quarters of Q2 fiscal year 2026 revenue. TMTT generated revenue of $195.9 million and growth of 44.8%, driven by contributions from PASCAL, EVOQUE, and SAPIEN M3, while surgical product revenue rose 5% to $284 million. On a trailing twelve-month basis in 2026, the latest EDGAR data showed revenue of $6.5 billion, gross profit of $5.1 billion, and net income of $1 billion.
Analyst consensus rates EW shares as a “Buy,” with an average target of $101.7 and a relatively wide range of $85 to $110. The average is approximately 5.6% above the 52-week range high of $96.29, while the lowest target falls within the 52-week range of $72.3–$96.29, reflecting differing assessments of the sustainability of TMTT and TAVR growth versus the risks of a second-half slowdown and currency and tax pressures. The information does not include a valid earnings multiple that can be used as an additional valuation anchor.
Figures in the text are as of 2026-09-02; the live price is shown at the top of the page.
TAVR was the largest driver, with global revenue of $1.3 billion in Q2 fiscal year 2026, compared with total revenue of $1.74 billion. The platform grew 10.5% year over year, supported by SAPIEN adoption and continued procedure growth at similar rates in the United States and abroad. Management raised its fiscal year 2026 TAVR sales growth forecast to 8%–9% and estimated annual sales of between $4.75 billion and $5 billion at the exchange rates used on July 23, 2026.
TMTT revenue rose 44.8% to $195.9 million in Q2 fiscal year 2026. Growth came from all three platforms together: PASCAL, EVOQUE, and SAPIEN M3, with PASCAL the largest by revenue, EVOQUE the second-largest and growing rapidly, and SAPIEN M3 the smallest because of its recent launch. The company raised its fiscal year 2026 TMTT revenue forecast to $760–$780 million and is targeting $2 billion in 2030.
Automated analysis for informational purposes only — not investment advice.
Adjusted earnings per share were $0.78 in Q2 fiscal year 2026, exceeding the $0.74 forecast cited in the news. Generally accepted accounting principles earnings per share were $0.42, primarily affected by a change in California law related to research and development credits. EDGAR data recorded net income of $241.9 million, while the company maintained its fiscal year 2026 adjusted earnings per share forecast at $2.95–$3.05.
The adjusted gross profit margin was 77.6% in Q2 fiscal year 2026, and currencies reduced this margin by 70 basis points compared with the previous year. Management expects the annual gross margin to finish at the lower end of the 78%–79% range, with an estimated currency headwind of approximately $35 million in the second half. It also expects an effective tax rate at the upper end of the 16%–19% range due to Pillar Two and the restrictions California imposed on research and development credits.
PARTNER 3 data demonstrated SAPIEN's performance and durability over seven years, while a five-year EARLY TAVR analysis added evidence regarding the treatment of aortic stenosis at an earlier stage. PASCAL PRECISION data demonstrated sustained safety and efficacy for one year in more than 4,600 U.S. patients with degenerative mitral regurgitation. In surgery, the COMMENCE study presented ten-year data showing favorable freedom from structural valve deterioration and a very low reoperation rate associated with this deterioration.
Analyst consensus is a “Buy,” with an average price target of $101.7, a high target of $110, and a low target of $85. The average target exceeds the 52-week range high of $96.29 by approximately 5.6%, while the lowest target remains within the $72.3–$96.29 range. The breadth of the targets indicates differing analyst estimates regarding the value of TMTT growth and the raised guidance versus revenue concentration in TAVR, margin pressures, and more difficult comparisons in the second half of fiscal year 2026.